טוען...
Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT
Grades 2-4 acute graft-versus-host disease (GVHD) occurs in approximately 35% of matched, related donor (MRD) allogeneic hematopoietic cell transplantation (HCT) recipients. We sought to determine if the combination of tacrolimus and sirolimus (Tac/Sir) was more effective than tacrolimus and methotr...
שמור ב:
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
פורמט: | Artigo |
שפה: | Inglês |
יצא לאור: |
American Society of Hematology
2014
|
נושאים: | |
גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4141519/ https://ncbi.nlm.nih.gov/pubmed/24982504 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-04-567164 |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|